Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide

MD. Merkerova, Z. Krejcik, M. Belickova, A. Hrustincova, J. Klema, E. Stara, Z. Zemanova, K. Michalova, J. Cermak, A. Jonasova,

. 2015 ; 95 (1) : 35-43. [pub] 20141111

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16010726

Grant support
NT13847 MZ0 CEP Register

OBJECTIVES: Lenalidomide is a potent drug with pleiotropic effects in patients with myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 [del(5q)]. We investigated its effect on regulation of microRNA (miRNA) expression profiles in del(5q) patients with MDS in vivo. METHODS: We used miRNA expression microarrays to study changes in miRNA levels in peripheral blood CD14+ monocytes collected from patients before and during lenalidomide treatment and compared them with those from healthy donors. RESULTS: Before treatment, we observed strong upregulation of pro-apoptotic miR-34a and miR-34a* that diminished during lenalidomide exposure. Upregulation of HOX-related miR-196b and erythroid-specific miR-451 seen in untreated patients remained unchanged after the treatment. At the time of hematologic response, expression of several miRNAs clustering to the 14q32 locus was reduced. Additionally, we focused more deeply on miRNAs from the 5q commonly deleted region and found that levels of miR-378 and miR-378* followed haploinsufficiency trend. CONCLUSIONS: This report describes changes in miRNA expression in del(5q) patients with MDS treated with lenalidomide, likely arising from deregulation of pathways implicated in lenalidomide action.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010726
003      
CZ-PrNML
005      
20191029104809.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12458 $2 doi
024    7_
$a 10.1111/ejh.12458 $2 doi
035    __
$a (PubMed)25287904
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dostálová, Michaela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0164071
245    10
$a Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide / $c MD. Merkerova, Z. Krejcik, M. Belickova, A. Hrustincova, J. Klema, E. Stara, Z. Zemanova, K. Michalova, J. Cermak, A. Jonasova,
520    9_
$a OBJECTIVES: Lenalidomide is a potent drug with pleiotropic effects in patients with myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 5 [del(5q)]. We investigated its effect on regulation of microRNA (miRNA) expression profiles in del(5q) patients with MDS in vivo. METHODS: We used miRNA expression microarrays to study changes in miRNA levels in peripheral blood CD14+ monocytes collected from patients before and during lenalidomide treatment and compared them with those from healthy donors. RESULTS: Before treatment, we observed strong upregulation of pro-apoptotic miR-34a and miR-34a* that diminished during lenalidomide exposure. Upregulation of HOX-related miR-196b and erythroid-specific miR-451 seen in untreated patients remained unchanged after the treatment. At the time of hematologic response, expression of several miRNAs clustering to the 14q32 locus was reduced. Additionally, we focused more deeply on miRNAs from the 5q commonly deleted region and found that levels of miR-378 and miR-378* followed haploinsufficiency trend. CONCLUSIONS: This report describes changes in miRNA expression in del(5q) patients with MDS treated with lenalidomide, likely arising from deregulation of pathways implicated in lenalidomide action.
650    _2
$a senioři $7 D000368
650    _2
$a makrocytární anemie $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D000748
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a chromozomální delece $7 D002872
650    _2
$a lidské chromozomy, pár 14 $7 D002883
650    _2
$a lidské chromozomy, pár 5 $x genetika $x metabolismus $7 D002895
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a genetické lokusy $7 D056426
650    _2
$a celogenomová asociační studie $7 D055106
650    _2
$a haploinsuficience $7 D057895
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x terapeutické užití $7 D007155
650    _2
$a leukocyty mononukleární $x účinky léků $x metabolismus $x patologie $7 D007963
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $x metabolismus $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a myelodysplastické syndromy $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D009190
650    _2
$a primární buněčná kultura $7 D061251
650    _2
$a sestřih RNA $7 D012326
650    _2
$a signální transdukce $7 D015398
650    _2
$a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krejčík, Zdeněk $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0125786
700    1_
$a Beličková, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0099634
700    1_
$a Hruštincová, Andrea $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0242102
700    1_
$a Kléma, Jiří, $u Department of Cybernetics, Faculty of Electrical Engineering, Czech Technical University, Prague, Czech Republic. $d 1971- $7 ntka172916
700    1_
$a Stara, Eliška $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Zemanová, Zuzana, $u Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1962- $7 nlk20050170627
700    1_
$a Michalová, Kyra, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1942- $7 nlk19990073558
700    1_
$a Čermák, Jaroslav, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1954- $7 xx0053072
700    1_
$a Jonášová, Anna $u First Department of Medicine, General University Hospital, Prague, Czech Republic. $7 xx0103767
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 95, č. 1 (2015), s. 35-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25287904 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20191029105248 $b ABA008
999    __
$a ok $b bmc $g 1114155 $s 935094
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 95 $c 1 $d 35-43 $e 20141111 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$a NT13847 $p MZ0
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options